Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
68Ga
bispecific antibody
breast cancer
immuno-PET
pretargeting
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
09
2019
accepted:
04
12
2019
pubmed:
15
3
2020
medline:
30
12
2020
entrez:
15
3
2020
Statut:
ppublish
Résumé
This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)-negative, carcinoembryonic antigen (CEA)-positive metastatic breast cancer, compared with CT, bone MRI, and
Identifiants
pubmed: 32169921
pii: jnumed.119.236000
doi: 10.2967/jnumed.119.236000
pmc: PMC7413237
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1205-1211Informations de copyright
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Références
J Nucl Med. 1993 Aug;34(8):1267-73
pubmed: 8326383
EJNMMI Res. 2011 Sep 01;1(1):20
pubmed: 22214534
Tumour Biol. 2005 Nov-Dec;26(6):281-93
pubmed: 16254457
Eur J Cancer. 2014 Sep;50(14):2508-16
pubmed: 25027745
Cancer Res. 1980 Aug;40(8 Pt 2):2984-92
pubmed: 7397693
PLoS One. 2016 Jul 27;11(7):e0158634
pubmed: 27462980
J Nucl Med. 2016 Oct;57(10):1505-1511
pubmed: 27230928
Mol Imaging Biol. 2014 Jun;16(3):431-40
pubmed: 24170452
Pathol Res Pract. 1985 Nov;180(5):490-7
pubmed: 3001680
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
EJNMMI Res. 2012 Jan 27;2:5
pubmed: 22284761
N Engl J Med. 1978 Jun 22;298(25):1384-6
pubmed: 349387
J Nucl Med. 2018 Jun;59(6):900-906
pubmed: 29146695
Clin Cancer Res. 2018 Oct 15;24(20):4988-4996
pubmed: 29980531
J Nucl Med. 1998 Jul;39(7):1172-8
pubmed: 9669389
Int J Cancer. 1991 Apr 1;47(6):865-9
pubmed: 2010229
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50
pubmed: 31637482
J Clin Oncol. 2017 Oct 10;35(29):3338-3346
pubmed: 28817371
Anticancer Res. 2007 Jul-Aug;27(4A):1963-8
pubmed: 17649806
Dtsch Arztebl Int. 2010 Feb;107(6):85-91
pubmed: 20204119
J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7
pubmed: 17878252
Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6
pubmed: 16636283
Br J Cancer. 2013 Aug 20;109(4):934-42
pubmed: 23860529
Front Pharmacol. 2016 May 24;7:131
pubmed: 27252651
World J Surg Oncol. 2018 Feb 12;16(1):26
pubmed: 29433529
Breast Cancer (Dove Med Press). 2017 Jul 04;9:461-471
pubmed: 28740429
Cancer. 2000 Jul 1;89(1):104-15
pubmed: 10897007
Eur Radiol. 2011 Dec;21(12):2604-17
pubmed: 21887484
Appl Radiat Isot. 2013 Jun;76:55-62
pubmed: 23063597
Cell. 1989 Apr 21;57(2):327-34
pubmed: 2702691
Dis Markers. 2018 May 2;2018:9863092
pubmed: 29854028